Dr. Shernan Holtan is Professor of Medicine and chief of the Blood and Marrow Transplant Service at Roswell Park Comprehensive Cancer Center. She specializes in developing non-immunosuppressive therapies and monitoring strategies for transplant and cell therapy complications. Her research on acute Graft-versus-Host Disease (GVHD) focuses on enhancing tissue repair rather than solely on immune suppression, particularly in high-risk patients. Dr. Holtan developed a biomarker, amphiregulin (AREG), for acute GI GVHD, validated through multicenter studies. Her findings on the role of DNA damage and stress responses in GVHD have highlighted the limitations of standard immunosuppression. As a principal investigator collaborating with Dr. Brian Betts, she identified pathogenic CD83 expression in lymphocyte subsets in acute and chronic GVHD and contributed to the establishment of PTCy-based GVHD prophylaxis as a new standard worldwide.